Zura Bio Limited Class A Ordinary Shares (ZURA)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Zura Bio Limited Class A Ordinary Shares (ZURA) is listed on Nasdaq, where it has traded since March 21, 2023.
- Listed On
- Nasdaq
- Listed Since
- March 21, 2023
- Employees
- 40
- Market Cap
- $399M
About Zura Bio Limited Class A Ordinary Shares
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 92 institutions reported holding ZURA, with 72.9 million shares worth $428.9 million in aggregate. The largest reported holder was Suvretta Capital Management, with 9.4 million shares worth $55.7 million. Of the 5 largest holders listed below, 1 opened a new position in ZURA, 1 added shares, 1 reduced its position and 2 held their positions unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Suvretta Capital Management | 9,443,001 | $56M | Added 4.15% |
| VR Adviser | 6,434,990 | $38M | Unchanged |
| Mpm Bioimpact | 4,472,843 | $26M | New position |
| JPMorgan Chase | 4,354,715 | $25M | Reduced 2.34% |
| Great Point Partners | 4,215,930 | $25M | Unchanged |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is ZURA?
Zura Bio Limited Class A Ordinary Shares (ZURA) is listed on Nasdaq, where it has traded since March 21, 2023.
Who are the largest institutional holders of ZURA?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of ZURA were Suvretta Capital Management, VR Adviser and Mpm Bioimpact.
How many institutions own ZURA?
92 institutions reported a position in ZURA for the quarter ended June 30, 2026, worth $428.9 million in total.
Did institutions buy or sell ZURA last quarter?
Of the 5 largest reported holders, 1 opened a new position in ZURA, 1 added shares, 1 reduced its position and 2 held their positions unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for ZURA.
Every reported institutional holder, plus insider and congressional trades in ZURA, on SentiSense.